IBDEI0E2 ; ; 18-NOV-2013
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;NOV 18, 2013
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,18831,0)
 ;;=207.12^^117^1098^7
 ;;^UTILITY(U,$J,358.3,18831,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18831,1,1,0)
 ;;=1^207.12
 ;;^UTILITY(U,$J,358.3,18831,1,8,0)
 ;;=8^Chr Erythremia in Relapse
 ;;^UTILITY(U,$J,358.3,18831,2)
 ;;=^336482
 ;;^UTILITY(U,$J,358.3,18832,0)
 ;;=207.20^^117^1098^28
 ;;^UTILITY(U,$J,358.3,18832,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18832,1,1,0)
 ;;=1^207.20
 ;;^UTILITY(U,$J,358.3,18832,1,8,0)
 ;;=8^Megakaryocytic Leuk w/o Remission
 ;;^UTILITY(U,$J,358.3,18832,2)
 ;;=^336868
 ;;^UTILITY(U,$J,358.3,18833,0)
 ;;=207.21^^117^1098^27
 ;;^UTILITY(U,$J,358.3,18833,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18833,1,1,0)
 ;;=1^207.21
 ;;^UTILITY(U,$J,358.3,18833,1,8,0)
 ;;=8^Megakaryocytic Leuk in Remission
 ;;^UTILITY(U,$J,358.3,18833,2)
 ;;=^267560
 ;;^UTILITY(U,$J,358.3,18834,0)
 ;;=207.22^^117^1098^26
 ;;^UTILITY(U,$J,358.3,18834,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18834,1,1,0)
 ;;=1^207.22
 ;;^UTILITY(U,$J,358.3,18834,1,8,0)
 ;;=8^Megakaryocytic Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,18834,2)
 ;;=^336483
 ;;^UTILITY(U,$J,358.3,18835,0)
 ;;=207.80^^117^1098^47
 ;;^UTILITY(U,$J,358.3,18835,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18835,1,1,0)
 ;;=1^207.80
 ;;^UTILITY(U,$J,358.3,18835,1,8,0)
 ;;=8^Oth Spec Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,18835,2)
 ;;=^336869
 ;;^UTILITY(U,$J,358.3,18836,0)
 ;;=207.81^^117^1098^46
 ;;^UTILITY(U,$J,358.3,18836,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18836,1,1,0)
 ;;=1^207.81
 ;;^UTILITY(U,$J,358.3,18836,1,8,0)
 ;;=8^Oth Spec Leukemia in Remission
 ;;^UTILITY(U,$J,358.3,18836,2)
 ;;=^267562
 ;;^UTILITY(U,$J,358.3,18837,0)
 ;;=207.82^^117^1098^45
 ;;^UTILITY(U,$J,358.3,18837,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18837,1,1,0)
 ;;=1^207.82
 ;;^UTILITY(U,$J,358.3,18837,1,8,0)
 ;;=8^Oth Spec Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,18837,2)
 ;;=^336484
 ;;^UTILITY(U,$J,358.3,18838,0)
 ;;=208.00^^117^1098^21
 ;;^UTILITY(U,$J,358.3,18838,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18838,1,1,0)
 ;;=1^208.00
 ;;^UTILITY(U,$J,358.3,18838,1,8,0)
 ;;=8^Leukemia Unspec w/o Remission
 ;;^UTILITY(U,$J,358.3,18838,2)
 ;;=^336870
 ;;^UTILITY(U,$J,358.3,18839,0)
 ;;=208.01^^117^1098^20
 ;;^UTILITY(U,$J,358.3,18839,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18839,1,1,0)
 ;;=1^208.01
 ;;^UTILITY(U,$J,358.3,18839,1,8,0)
 ;;=8^Leukemia Unspec in Remission
 ;;^UTILITY(U,$J,358.3,18839,2)
 ;;=^267566
 ;;^UTILITY(U,$J,358.3,18840,0)
 ;;=208.02^^117^1098^19
 ;;^UTILITY(U,$J,358.3,18840,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18840,1,1,0)
 ;;=1^208.02
 ;;^UTILITY(U,$J,358.3,18840,1,8,0)
 ;;=8^Leukemia Unspec in Relapse
 ;;^UTILITY(U,$J,358.3,18840,2)
 ;;=^336485
 ;;^UTILITY(U,$J,358.3,18841,0)
 ;;=208.10^^117^1098^12
 ;;^UTILITY(U,$J,358.3,18841,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18841,1,1,0)
 ;;=1^208.10
 ;;^UTILITY(U,$J,358.3,18841,1,8,0)
 ;;=8^Chr Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,18841,2)
 ;;=^336871
 ;;^UTILITY(U,$J,358.3,18842,0)
 ;;=208.11^^117^1098^11
 ;;^UTILITY(U,$J,358.3,18842,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18842,1,1,0)
 ;;=1^208.11
 ;;^UTILITY(U,$J,358.3,18842,1,8,0)
 ;;=8^Chr Leukemia in Remission
 ;;^UTILITY(U,$J,358.3,18842,2)
 ;;=^267569
 ;;^UTILITY(U,$J,358.3,18843,0)
 ;;=208.12^^117^1098^10
 ;;^UTILITY(U,$J,358.3,18843,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18843,1,1,0)
 ;;=1^208.12
 ;;^UTILITY(U,$J,358.3,18843,1,8,0)
 ;;=8^Chr Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,18843,2)
 ;;=^336486
 ;;^UTILITY(U,$J,358.3,18844,0)
 ;;=208.20^^117^1098^53
 ;;^UTILITY(U,$J,358.3,18844,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18844,1,1,0)
 ;;=1^208.20
 ;;^UTILITY(U,$J,358.3,18844,1,8,0)
 ;;=8^Subacute Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,18844,2)
 ;;=^336872
 ;;^UTILITY(U,$J,358.3,18845,0)
 ;;=208.21^^117^1098^52
 ;;^UTILITY(U,$J,358.3,18845,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18845,1,1,0)
 ;;=1^208.21
 ;;^UTILITY(U,$J,358.3,18845,1,8,0)
 ;;=8^Subacute Leukemia in Remission
 ;;^UTILITY(U,$J,358.3,18845,2)
 ;;=^267572
 ;;^UTILITY(U,$J,358.3,18846,0)
 ;;=208.22^^117^1098^51
 ;;^UTILITY(U,$J,358.3,18846,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18846,1,1,0)
 ;;=1^208.22
 ;;^UTILITY(U,$J,358.3,18846,1,8,0)
 ;;=8^Subacute Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,18846,2)
 ;;=^336487
 ;;^UTILITY(U,$J,358.3,18847,0)
 ;;=208.80^^117^1098^38
 ;;^UTILITY(U,$J,358.3,18847,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18847,1,1,0)
 ;;=1^208.80
 ;;^UTILITY(U,$J,358.3,18847,1,8,0)
 ;;=8^Oth Leuk Unspec Cell Type w/o Rem
 ;;^UTILITY(U,$J,358.3,18847,2)
 ;;=^336873
 ;;^UTILITY(U,$J,358.3,18848,0)
 ;;=208.81^^117^1098^37
 ;;^UTILITY(U,$J,358.3,18848,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18848,1,1,0)
 ;;=1^208.81
 ;;^UTILITY(U,$J,358.3,18848,1,8,0)
 ;;=8^Oth Leuk Unspec Cell Type w/ Rem
 ;;^UTILITY(U,$J,358.3,18848,2)
 ;;=^267574
 ;;^UTILITY(U,$J,358.3,18849,0)
 ;;=208.82^^117^1098^36
 ;;^UTILITY(U,$J,358.3,18849,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18849,1,1,0)
 ;;=1^208.82
 ;;^UTILITY(U,$J,358.3,18849,1,8,0)
 ;;=8^Oth Leuk Unspec Cell Type in Relap
 ;;^UTILITY(U,$J,358.3,18849,2)
 ;;=^336488
 ;;^UTILITY(U,$J,358.3,18850,0)
 ;;=209.00^^117^1098^25
 ;;^UTILITY(U,$J,358.3,18850,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18850,1,1,0)
 ;;=1^209.00
 ;;^UTILITY(U,$J,358.3,18850,1,8,0)
 ;;=8^Mal Carcinoid Tumor,Sm Intestine
 ;;^UTILITY(U,$J,358.3,18850,2)
 ;;=^336721
 ;;^UTILITY(U,$J,358.3,18851,0)
 ;;=209.01^^117^1098^22
 ;;^UTILITY(U,$J,358.3,18851,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18851,1,1,0)
 ;;=1^209.01
 ;;^UTILITY(U,$J,358.3,18851,1,8,0)
 ;;=8^Mal Carcinoid Tumor,Duodenum
 ;;^UTILITY(U,$J,358.3,18851,2)
 ;;=^336490
 ;;^UTILITY(U,$J,358.3,18852,0)
 ;;=209.02^^117^1098^24
 ;;^UTILITY(U,$J,358.3,18852,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18852,1,1,0)
 ;;=1^209.02
 ;;^UTILITY(U,$J,358.3,18852,1,8,0)
 ;;=8^Mal Carcinoid Tumor,Jejunum
 ;;^UTILITY(U,$J,358.3,18852,2)
 ;;=^336491
 ;;^UTILITY(U,$J,358.3,18853,0)
 ;;=209.03^^117^1098^23
 ;;^UTILITY(U,$J,358.3,18853,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18853,1,1,0)
 ;;=1^209.03
 ;;^UTILITY(U,$J,358.3,18853,1,8,0)
 ;;=8^Mal Carcinoid Tumor,Ileum
 ;;^UTILITY(U,$J,358.3,18853,2)
 ;;=^336492
 ;;^UTILITY(U,$J,358.3,18854,0)
 ;;=204.00^^117^1099^1
 ;;^UTILITY(U,$J,358.3,18854,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18854,1,1,0)
 ;;=1^204.00
 ;;^UTILITY(U,$J,358.3,18854,1,8,0)
 ;;=8^ALL w/o Remission
 ;;^UTILITY(U,$J,358.3,18854,2)
 ;;=^267521
 ;;^UTILITY(U,$J,358.3,18855,0)
 ;;=204.01^^117^1099^3
 ;;^UTILITY(U,$J,358.3,18855,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18855,1,1,0)
 ;;=1^204.01
 ;;^UTILITY(U,$J,358.3,18855,1,8,0)
 ;;=8^ALL,in Remission
 ;;^UTILITY(U,$J,358.3,18855,2)
 ;;=^267522
 ;;^UTILITY(U,$J,358.3,18856,0)
 ;;=204.10^^117^1099^5
 ;;^UTILITY(U,$J,358.3,18856,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18856,1,1,0)
 ;;=1^204.10
 ;;^UTILITY(U,$J,358.3,18856,1,8,0)
 ;;=8^CLL w/o Remission
 ;;^UTILITY(U,$J,358.3,18856,2)
 ;;=^267523
 ;;^UTILITY(U,$J,358.3,18857,0)
 ;;=204.11^^117^1099^7
 ;;^UTILITY(U,$J,358.3,18857,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18857,1,1,0)
 ;;=1^204.11
 ;;^UTILITY(U,$J,358.3,18857,1,8,0)
 ;;=8^CLL,in Remission
 ;;^UTILITY(U,$J,358.3,18857,2)
 ;;=^267524
 ;;^UTILITY(U,$J,358.3,18858,0)
 ;;=201.90^^117^1099^11
 ;;^UTILITY(U,$J,358.3,18858,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18858,1,1,0)
 ;;=1^201.90
 ;;^UTILITY(U,$J,358.3,18858,1,8,0)
 ;;=8^Hodgkin's Lymphoma,Unspec Type
 ;;^UTILITY(U,$J,358.3,18858,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,18859,0)
 ;;=202.00^^117^1099^19
 ;;^UTILITY(U,$J,358.3,18859,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18859,1,1,0)
 ;;=1^202.00
 ;;^UTILITY(U,$J,358.3,18859,1,8,0)
 ;;=8^Lymphoma,Low-Grade (Nodular)
 ;;^UTILITY(U,$J,358.3,18859,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,18860,0)
 ;;=200.20^^117^1099^16
 ;;^UTILITY(U,$J,358.3,18860,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18860,1,1,0)
 ;;=1^200.20
 ;;^UTILITY(U,$J,358.3,18860,1,8,0)
 ;;=8^Lymphoma,Burkitts
 ;;^UTILITY(U,$J,358.3,18860,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,18861,0)
 ;;=202.10^^117^1099^29
 ;;^UTILITY(U,$J,358.3,18861,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18861,1,1,0)
 ;;=1^202.10
 ;;^UTILITY(U,$J,358.3,18861,1,8,0)
 ;;=8^Mycosis Fungoides
 ;;^UTILITY(U,$J,358.3,18861,2)
 ;;=^80360
 ;;^UTILITY(U,$J,358.3,18862,0)
 ;;=273.3^^117^1099^21
 ;;^UTILITY(U,$J,358.3,18862,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18862,1,1,0)
 ;;=1^273.3
 ;;^UTILITY(U,$J,358.3,18862,1,8,0)
 ;;=8^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,18862,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,18863,0)
 ;;=203.00^^117^1099^28
 ;;^UTILITY(U,$J,358.3,18863,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18863,1,1,0)
 ;;=1^203.00
 ;;^UTILITY(U,$J,358.3,18863,1,8,0)
 ;;=8^Multiple Myeloma,W/O Remission
 ;;^UTILITY(U,$J,358.3,18863,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,18864,0)
 ;;=203.01^^117^1099^27
 ;;^UTILITY(U,$J,358.3,18864,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18864,1,1,0)
 ;;=1^203.01
 ;;^UTILITY(U,$J,358.3,18864,1,8,0)
 ;;=8^Multiple Myeloma,In Remission
 ;;^UTILITY(U,$J,358.3,18864,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,18865,0)
 ;;=202.40^^117^1099^8
 ;;^UTILITY(U,$J,358.3,18865,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18865,1,1,0)
 ;;=1^202.40
 ;;^UTILITY(U,$J,358.3,18865,1,8,0)
 ;;=8^Hairy-Cell Leukemia
 ;;^UTILITY(U,$J,358.3,18865,2)
 ;;=^69587
 ;;^UTILITY(U,$J,358.3,18866,0)
 ;;=200.10^^117^1099^18
 ;;^UTILITY(U,$J,358.3,18866,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,18866,1,1,0)
 ;;=1^200.10
 ;;^UTILITY(U,$J,358.3,18866,1,8,0)
 ;;=8^Lymphoma,Int/High (Diffuse)
 ;;^UTILITY(U,$J,358.3,18866,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,18867,0)
 ;;=273.1^^117^1099^25
 ;;^UTILITY(U,$J,358.3,18867,1,0)
 ;;=^358.31IA^8^2
